ArticleIndian pediatrics2025
Organochlorine Pesticide Residues in Children with Hematological Disorders.
Article in Indian pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diazinon may increase the risk of acute lymphoblastic leukemia by inducingEnvironmental epigenetics · 2026Article
- Pesticide Exposure and Hematological Disorders-is There a Link?Indian pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the levels of organochlorine pesticide (OCP) residues in sera and bone marrow of children with malignant and non-malignant hematological disorders (HDs) with those in healthy controls.
methodsThis case-control study was conducted among children aged ≤ 12 years with malignant and non-malignant HDs and non-anemic healthy controls. Children with gross congenital malformations, neurodevelopmental disorders, and chronic systemic diseases were excluded. OCPs were estimated in sera and bone marrow aspirate using gas-liquid chromatography/
resultsThirty children, each, with malignant HDs, non-malignant HDs, and controls, were included. The median (Q1, Q3) serum total OCPs (ng/mL) were significantly higher in children with malignant and non-malignant HDs compared to controls [38.67 (33.64, 42.51); 32.72 (17.26, 41.60); and 14.11 (12.82, 16.40)]; levels were significantly higher in the malignant versus non-malignant HD group. The median (Q1, Q3) serum levels of total hexachlorocyclohexane [3.30 (2.23, 4.28) vs. 2.16 (1.31, 3.31) ng/mL] and β-hexachlorocyclohexane [0.98 (0.67, 1.68) vs. 0.54 (0.10, 0.77) ng/mL] levels were significantly higher in children with non-malignant HDs compared to malignant HD, respectively. The median (Q1, Q3) total bone marrow OCPs (ng/mL) were significantly higher in the malignant HD group [23.53 (20.83, 26.91)] compared to the non-malignant HD group [17.41 (0, 25.63)]; bone marrow endosulfan II (ng/mL) was significantly higher in the non-malignant HD group [1.56 (0.56, 3.89)] compared to malignant HD group [0.45 (0.35, 1.72)].
conclusionChildren with HDs had significantly higher OCP residues in sera compared to controls. The cumulative OCP residues in sera and bone marrow were significantly higher in children with malignant versus non-malignant HDs.
Indexed as
Identifiers
40828229What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.